Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIAGARA phase 3 trial of durvalumab plus gemcitabine/cisplatin in muscle-invasive bladder cancer
MOH_2019-01-07_004864Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in bladder cancer, muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Time to disease progression and Overall survival. Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2019-01-07_004864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-07_004864.